



Drug Resistance of Head and Neck Cancer

Guest Editor:

Dr. Ali Khammanivong

Dickerson Laboratory, Masonic
Cancer Center, University of
Minnesota, 420 Delaware Street
SE, Minneapolis, MN 55455, USA

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Drug resistance in head and neck cancer (HNC) remains a major health problem worldwide. HNC can arise in the lips, oral cavity, nasal cavity, pharynx, larynx, and salivary glands, and accounts for approximately 890,000 new cases and more than 450,000 deaths each year. The majority of HNC occurs in the oral cavity and approx. 90% of HNC is categorized as head and neck squamous cell carcinoma. Despite the recent advances in therapeutic modalities, the prognosis and 5-year survival rates for patients with advanced, recurrent, and metastatic diseases remain poor due to treatment resistance. The current standard-of-care for HNC involves surgical removal combined with radiation and chemotherapy or immunotherapy. Unfortunately, more than half of locally advanced HNC cases recur or become metastatic following initial treatments and are no longer responsive. Multidrug resistance and survival mechanisms driving drug efflux, metabolism, noncoding RNAs, and cancer stem cells are known to contribute to the resistance in HNC and remain to be fully explored. The current Special Issue will address the current status and future novel directions for understanding drug resistance in HNC.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Jukka Finne

Research Programme in
Molecular and Integrative
Biosciences, Faculty of Biological
and Environmental Sciences,
University of Helsinki, P.O. Box
56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya

Integrative Systems Biology
Institute, University of Valencia
and CSIC, 46980 Valencia, Spain

Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biology) / CiteScore - Q1 (General Agricultural and Biological Sciences)

Contact Us

Biology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biology
biology@mdpi.com
[X@Biology_MDPI](https://twitter.com/Biology_MDPI)